Beam Therapeutics Inc. Common Stock (BEAM)

Price$30.33

Favorite Metrics

Price vs S&P 500 (26W)9.64%

Price vs S&P 500 (4W)15.35%

Market Capitalization$3.12B

All Metrics

Book Value / Share (Quarterly)$12.17

P/TBV (Annual)3.30x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)31.88%

Cash Flow / Share (Quarterly)$-3.54

Price vs S&P 500 (YTD)8.04%

Net Profit Margin (TTM)-57.24%

EPS (TTM)$-0.97

10-Day Avg Trading Volume2.04M

EPS Excl Extra (TTM)$-0.97

Revenue Growth (5Y)487.30%

EPS (Annual)$-0.81

ROI (Annual)-6.46%

Net Profit Margin (5Y Avg)-374.99%

Cash / Share (Quarterly)$12.24

Revenue Growth QoQ (YoY)279.52%

ROA (Last FY)-5.40%

Revenue Growth TTM (YoY)120.01%

EBITD / Share (TTM)$-3.65

ROE (5Y Avg)-31.11%

Operating Margin (TTM)-274.57%

Cash Flow / Share (Annual)$-3.54

P/B Ratio2.52x

P/B Ratio (Quarterly)2.27x

Net Income / Employee (Annual)$-0

EV / Revenue (TTM)20.25x

Net Interest Coverage (TTM)-365.97x

ROA (TTM)-5.66%

EPS Incl Extra (Annual)$-0.81

Current Ratio (Annual)13.09x

Quick Ratio (Quarterly)12.85x

3-Month Avg Trading Volume1.90M

52-Week Price Return80.47%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$9.81

P/S Ratio (Annual)22.36x

Asset Turnover (Annual)0.09x

52-Week High$36.44

Operating Margin (5Y Avg)-457.65%

EPS Excl Extra (Annual)$-0.81

CapEx CAGR (5Y)-1.79%

26-Week Price Return13.63%

Quick Ratio (Annual)12.85x

13-Week Price Return-8.93%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)13.09x

Enterprise Value$2,830.006

Revenue / Share Growth (5Y)412.40%

Asset Turnover (TTM)0.10x

Book Value / Share Growth (5Y)23.21%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-57.24%

Cash / Share (Annual)$12.24

3-Month Return Std Dev83.62%

Net Income / Employee (TTM)$-0

ROE (Last FY)-6.46%

Net Interest Coverage (Annual)-9.73x

EPS Basic Excl Extra (Annual)$-0.81

Receivables Turnover (TTM)0.41x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.97

Receivables Turnover (Annual)0.41x

ROI (TTM)-7.31%

P/S Ratio (TTM)22.36x

Pretax Margin (5Y Avg)-365.42%

Revenue / Share (Annual)$1.41

Tangible BV / Share (Annual)$10.29

Price vs S&P 500 (52W)50.64%

Year-to-Date Return10.68%

5-Day Price Return16.52%

EPS Normalized (Annual)$-0.81

ROA (5Y Avg)-19.06%

Net Profit Margin (Annual)-57.24%

Month-to-Date Return28.75%

Cash Flow / Share (TTM)$-3.96

EBITD / Share (Annual)$-3.65

Operating Margin (Annual)-274.57%

LT Debt / Equity (Annual)0.16x

ROI (5Y Avg)-31.02%

LT Debt / Equity (Quarterly)0.04x

EPS Basic Excl Extra (TTM)$-0.97

P/TBV (Quarterly)3.10x

P/B Ratio (Annual)2.27x

Pretax Margin (TTM)-57.24%

Book Value / Share (Annual)$12.17

Price vs S&P 500 (13W)-9.62%

Beta2.29x

Revenue / Share (TTM)$1.36

ROE (TTM)-7.31%

52-Week Low$15.35

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.30

4.33

4.32

Industry Peers — Biological Products(88)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
BEAMBeam Therapeutics Inc. Common Stock	22.36x	120.01%	—	—	$30.33
AMGNAmgen Inc	5.13x	9.95%	73.30%	2.93%	$349.39
GILDGilead Sciences Inc	5.84x	2.40%	78.83%	133.64%	$138.55
ARGXargenx SE American Depositary Shares	12.46x	89.56%	150.91%	—	$828.35
BNTXBioNTech SE American Depositary Share	8.75x	-11.81%	84.21%	—	$102.12
BIIBBiogen Inc. Common Stock	2.60x	2.22%	75.69%	-18.77%	$176.02
MRNAModerna, Inc. Common Stock	11.02x	-39.93%	70.32%	—	$54.68
NBIXNeurocrine Biosciences Inc	4.49x	21.45%	98.18%	2.31%	$128.41
EXELExelixis Inc	4.96x	6.85%	96.39%	31.10%	$44.38
TECHBio-Techne Corp.	7.60x	1.64%	66.60%	-20.58%	$57.36
HALOHalozyme Therapeutics, Inc.	5.74x	37.55%	83.62%	22.89%	$66.64

About

Beam Therapeutics is a precision genetic medicine company leveraging proprietary base editing technology to develop lifelong cures for serious diseases. The company's pipeline focuses on hematologic and genetic disorders, with lead programs including BEAM-101 for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency. Operations are based in the United States.